Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
Andrew H. Ko
Consultant or Advisory Role - Genentech/Roche
Margaret A. Tempero
No relevant relationships to disclose
Tanios B. Bekaii-Saab
Consultant or Advisory Role - Genentech/Roche
Peter Kuhn
Stock Ownership - Epic Sciences
Ryan Courtin
No relevant relationships to disclose
Sharvina Ziyeh
No relevant relationships to disclose
Sanaa Tahiri
No relevant relationships to disclose
Robin Katie Kelley
No relevant relationships to disclose
Elizabeth Dito
No relevant relationships to disclose
Anna Ong
No relevant relationships to disclose
Regina Linetskaya
No relevant relationships to disclose
Olga K. Mirzoeva
No relevant relationships to disclose
Christina Sing-Ying Wu
No relevant relationships to disclose
Alan Paul Venook
Research Funding - Genentech/Roche
Wolfgang Michael Korn
Honoraria - Genentech/Roche